The regulation of angiogenesis in neuroblastoma

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 47-52

  Chlenski, Alexandre ^a   Liu, Shuqing ^a   Cohn, Susan L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Amplification; Angiogenesis; Angiogenesis inhibitors; Angiogenesis stimulators; Matrix metalloproteinase; Metastasis; MYCN; Neuroblastoma; Pigment epithelium derived factor; Schwann cells; Vascular density; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOGENIN 1; ANGIOGENIN 2; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; OSTEONECTIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN C;

ANGIOGENESIS; CELL HETEROGENEITY; CHILDHOOD CANCER; CLINICAL FEATURE; CONFERENCE PAPER; CORRELATION ANALYSIS; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; INHIBITION KINETICS; NEURAL CREST; NEUROBLASTOMA; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STIMULATION; TUMOR VASCULARIZATION;

EID: 0038105514     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00082-X     Document Type: Conference Paper

References (26)

1. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
2. Brem S., Cotran R., Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl. Cancer Inst. 48:1972;347-356.
3. Brodeur G.M., Maris J.M. Neuroblastoma. Pizzo P.A., Poplack D.G. Principles and Practice of Pediatric Oncology. 2001;895-937 Lippincott-Raven, Philadelphia.
4. Meitar D., Crawford S.E., Rademaker A.W., Cohn S.L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14:1996;405-414.
5. Ribatti D., Surico G., Vacca A., De Leonardis F., Lastilla G., Montaldo P.G., Rigillo N., Ponzoni M. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 68:2001;1161-1168.
6. 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 60:2000;712-721.
7. Canete A., Navarro S., Bermudez J., Pellin A., Castel V., Llombart-Bosch A. Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J. Clin. Oncol. 18:2000;27-34.
8. Ribatti D., Alessandri G., Vacca A., Iurlaro M., Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int. J. Cancer. 77:1998;449-454.
9. Pavlakovic H., Von S., Rossler V.J., Koscielniak E., Havers W., Schweigerer L. Quantification of angiogenesis stimulators in children with solid malignancies. Int. J. Cancer. 92:2001;756-760.
10. Eggert A., Ikegaki N., Kwiatkowski J., Zhao H., Brodeur G.M., Himelstein B.P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6:2000;1900-1908.
11. Katzenstein H.M. The role of angiogenesis in neuroblastoma: clinical implications. Am. J. Cancer. 2003;in press.
12. Eggert A., Grotzer M.A., Ikegaki N., Liu X.G., Evans A.E., Brodeur G.M. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res. 62:2002;1802-1808.
13. Bouck N., Stellmach V., Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 69:1996;135-174.
14. Breit S., Ashman K., Wilting J., Rossler J., Hatzi E., Fotsis T., Schweigerer L. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as Activin A. Cancer Res. 60:2000;4596-4601.
15. Hatzi E., Murphy C., Zoephel A., Rasmussen H., Morbidelli L., Ahorn H., Kunisada K., Tontsch U., Klenk M., Yamauchi-Takihara K., Ziche M., Rofstad E.K., Schweigerer L., Fotsis T. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene. 21:2002;3552-3561.
16. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer. 86:1999;364-372.
17. Ambros I.M., Zellner A., Roald B., Amann G., Ladenstein R., Printz D., Gadner H., Ambros P.F. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N. Engl. J. Med. 334:1996;1505-1511.
18. Huang D., Rutkowski J.L., Brodeur G.M., Chou P.M., Kwiatkowski J.L., Babbo A., Cohn S.L. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res. 60:2000;5966-5971.
19. Crawford S.E., Stellmach V., Ranalli M., Huang X., Huang L., Volpert O., De Vries G.H., Abramson L.P., Bouck N. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J. Cell Sci. 114:2001;4421-4428.
20. Ray J.M., Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J. 7:1994;2062-2072.
21. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 285:1999;245-248.
22. Chlenski A., Liu S., Crawford S.E., Volpert O.V., DeVries G.H., Evangelista A., Yang Q., Salwen H.R., Farrer R., Bray J., Cohn S.L. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 62:2002;7357-7363.
23. Brekken R.A., Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 19:2000;569-580.
24. Ledda M.F., Adris S., Bravo A.I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O.L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3:1997;171-176.
25. Yiu G.K., Chan W.Y., Ng S.W., Chan P.S., Cheung K.K., Berkowitz R.S., Mok S.C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159:2001;609-622.
26. Katzenstein H.M., Rademaker A.W., Senger C., Salwen H., Nguyen N., Cohn S.L. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin. Cancer Res. 5:1999;4273-4278.